Press Releases

Jamie Cygielman will lead Zales’ next phase of growth and innovation, while Pam Cloud will lead Blue Nile’s transformation as an elevated luxury brand, anchored in natural diamonds Appointments advance Signet’s Grow Brand Love strategy to strengthen and differentiate its portfolio of brands Signet Jewelers, whose portfolio includes, KAY Jewelers, Zales, Jared Jewelers, Blue Nile and Banter, today announced two significant brand leadership appointments that advance the company’s Grow Brand Love strategy. Jamie Cygielman has been appointed President of Zales and Banter and Pam Cloud has joined Signet as President of Blue Nile. "Grow Brand Love is about creating distinctive brands with

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE:RHP) (the "Company") announced today that its subsidiaries, RHP Hotel Properties, LP (the "Operating Partnership") and RHP Finance Corporation (together with the Operating Partnership, the "Issuers"), intend to offer, in a private placement, subject to market and other conditions, $700 million aggregate principal amount of senior notes due 2035 (the "Notes"). The Notes will be senior unsecured obligations of the Issuers and guaranteed by the Company and its subsidiaries that guarantee the Operating Partnership’s existing credit facility and the Issuers’ outstanding senior unsecured notes. The Oper

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 StudyCash and cash equivalents of $9.5 million as of June 30, 2026Increased business development activitiesConference call begins at 8:00 a.m. Eastern time todaySHELTON, Conn., Aug. 11, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tum

PETAH TIKVA, Israel, Aug. 11, 2026 /PRNewswire/ -- Eltek Ltd. (NASDAQ:ELTK), a leading global manufacturer of high-quality printed circuit boards, announced today that it will release its financial results for the second quarter of 2026 before the market opens on Tuesday, August 18, 2026. Eltek's financial results will be released over the news wires and will be posted on its corporate website at: http://www.nisteceltek.com. On Tuesday, August 18, 2026, at 8:30 a.m. Eastern Time, Eltek will conduct a conference call to discuss the results. The call will feature remarks by Eli Yaffe, Chief Executive Officer and Ron Freund, Chief

Company Gains Access to Rare and Commercially Desirable High-Quality Lactoferrin for the Large and Rapidly Scaling Chinese Markets, Adding New Scientist to Drive New Product Development  NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Planet Green Holdings Corp. (NYSE American: PLAG) (the "Company"), operating a diversified portfolio of businesses, including consumer products and online advertising, today announced it has entered into commercial operations to source, market and distribute lactoferrin, a critical glycoprotein used in a wide range of health products, including the Company's chewable immune tablets. Lactoferrin is also widely used in infant formulas, sports nutrition, and a wide range

MIAMI, Aug. 11, 2026 /CNW/ -- Collective Mining Ltd. (NASDAQ:CNL) (TSX:CNL) ("Collective" or the "Company") is pleased to announce that its common shares will commence trading today on the Nasdaq Global Select Market® ("Nasdaq") under the symbol "CNL". As previously announced on July 29, 2026, the commencement of trading on the Nasdaq follows the voluntary transfer of the Company's U.S. stock exchange listing from the NYSE American, where its common shares ceased listing at market close on August 10, 2026.Collective's listing on the Toronto Stock Exchange remains unchanged. The Company's CUSIP number also remains unchanged, and

Littelfuse, Inc. (NASDAQ:LFUS), a leader in developing smart solutions that enable safe and efficient electrical energy transfer, today announced the appointment of Todd Kelsey to the company’s board of directors. Kelsey was also appointed to the Compensation Committee. "We are pleased to welcome Todd to the Littelfuse Board of Directors," said Gordon Hunter, Littelfuse Chairman of the Board of Directors. "Todd brings extensive global experience as well as technology, engineering, and manufacturing expertise across our end markets. His operational perspective, public company board experience, and track record of leading a multinational organization will be valuable as we continue to execu

Healthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA’s Launch Later This Year Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA® (copper intrauterine system) Risk Evaluation and Mitigation Strategy (REMS) Program is now open for enrollment at www.miudellarems.com. The website enables healthcare providers, healthcare settings, and eligible specialty pharmacies to complete the certification and enrollment activities required to support the dispensing and insertion of MIUDELLA. MIUD

Data from Phase 1/2 trial of NGN-401 for Rett syndrome showed 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant; no plateau and no milestone loss observed as of data cutoff date of June 16, 2026 Milestones gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment Topline data from Embolden™ registrational trial anticipated in 2H 2027 NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of August 10, 2026 Initiated PPQ campaign to support BLA submission for NGN-401; completion of PPQ runs expected by end of 2026 Extended cash

Positive topline results from open-label Phase 2 Study ‘207’ evaluating VDPHL01 in female pattern hair loss demonstrated rapid onset and consistent hair growth Completion of patient enrollment for Phase 2/3 Study ‘306’, a 556 participant, registration-directed trial evaluating VDPHL01 in female pattern hair loss, marking a milestone in the development of the potential first oral prescription treatment for women; topline readout anticipated in 1H27 VDPHL01 has the potential to be the first extended-release oral minoxidil therapy for women and men with pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United States Company remains on track

TibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027 Zura plans to initiate a Phase 2 study for tibulizumab in polymyalgia rheumatica (PMR) by year-end 2026 Cash and cash equivalents of $205.1 million as of June 30, 2026, which is expected to fund planned operations through at least the end of 2028 Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of pa

Delivered record quarterly net sales, increasing approximately 90% year-over-year, driven by strong demand for edge AI solutions Gross profit more than doubled year-over-year on higher net sales and margin expansion Expect third quarter net sales of $36.0 million to $37.0 million, which would represent the sixth consecutive quarter of sequential growth Ambiq Micro, Inc. ("Ambiq") (NYSE:AMBQ), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced financial results for the second quarter 2026. Second Quarter 2026 and Recent Highlights Delivered strong net sales on growing edge AI demand momentum: Net sales increased approximately 90%, year-over

President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027  Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors and serve as Strategic Advisor On track for substantial enrollment of pivotal FORTIFI-HN01 study by year-end, enabling topline results from interim analysis in mid-2027; initiated FORTIFI-FLEX alternate dosing study Company to host conference call and webcast today, Tuesday, August 11, 2026 at 8:30 am ET BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional

GREENWICH, Conn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Stardust Power Inc. (NASDAQ:SDST) ("Stardust Power" or the "Company"), an American developer of battery-grade lithium carbonate, today announced the appointment of Mr. V. Ray Rivers to its Board of Directors (the "Board"), effective August 10, 2026. Mr. Rivers will also serve as a member of the Audit Committee and Compensation Committee of the Board. Mr. Rivers brings more than three decades of experience in capital markets, institutional investments, and financial services. Throughout his career, he has held senior leadership positions with several leading Wall Street firms, including Bear Stearns, CRT Capital Group, Cantor Fitzgerald,

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity financing with gross proceeds of $175.0 million in April 2026 Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to severe acne FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysisDMC recommended that the TeLuRide-006 study continue as planned in all other respects MILLBRAE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in

WARREN, Mich., Aug. 11, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ:EVGO) ("EVgo"), one of the nation's largest public fast charging networks today announced the opening of its newest flagship charging station in metropolitan Detroit, further advancing the Company’s efforts to deploy high-power, customer-focused infrastructure in key markets across the country. With this new site, located in partnership with Midwest retailer, Meijer, more than 40 flagship charging stalls are now open nationwide, and EVgo expects to have over 100 flagship stalls online by the end of 2026. General Motors (GM) has contributed to this expansion to aid EV adoption across the U.S. EVgo flagships are designed to

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (NASDAQ:ZENA) (FSE: 49Q) (BMV:ZENA) ("ZenaTech"), a technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its U.S.-based subsidiary ZenaDrone has commenced flight testing of its custom-designed printed circuit boards (PCBs) at its UAE manufacturing and testing facility, integrating the proprietary boards directly into its ZenaDrone 1000 and IQ Nano drone platforms. The boards are designed and manufactured at the Company’s Taiwan-based Spider Vision Sensors (SVS) subsidiary, then shipped to UAE f

ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that all of the nominee directors listed in the management information circular dated June 22, 2026 were elected as directors of ATS. The vote was conducted electronically at the virtual Annual and Special Meeting of Shareholders, which took place on August 6, 2026 ("Annual Meeting"). The voting results based on votes cast by shareholders present online or represented by proxy at the Annual Meeting are set out below: Name of Nominee Votes For Percent Votes Withheld Percent Avik Dey 85,014,959 99.35% 556,503 0.65% Joanne S. Ferstman 84,619,00

CHICAGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nearly one-third of Gen Z drivers (30%) self-disclosed having owned or driven an uninsured vehicle over the past six months, making them the most likely generation to own or drive a vehicle without coverage, according to new research from TransUnion (NYSE:TRU). By comparison, 17% of Millennials owned or drove a vehicle uninsured, with rates declining further among Gen X (7%) and Baby Boomers (1%). As the Gen Z driving population grows, insurers face the challenge of identifying drivers in this generation at risk of coverage lapse. This topic and others are explored in TransUnion’s Q3 2026 Insurance Personal Lines Trends and Perspectives Quarterly